epilepsy seizure

South Korea’s SK Biopharmaceuticals Co. has signed a deal with Brazil’s Eurofarma Laboratórios S.A. to establish a joint venture ...

South Korea's SK Biopharmaceuticals Co. said on Tuesday it submitted the new drug application (NDA) for its flagship epilepsy drug Cenobamate to Chi...

South Korea's SK Biopharmaceuticals targeted 416 billion won ($311 million) for its epilepsy treatment Cenobamate in the US market this year. SK Bi...

SK Biopharmaceuticals Co. is gearing up to explore the European market for its flagship epilepsy drug Cenobamate, while looking for new mergers and ...

South Korea's SK Biopharmaceuticals announced on Friday an extension of its US patent for the epilepsy treatment Cenobamate, now set to expire on Oc...

South Korea's SK Biopharmaceuticals announced on Friday a strategic tie-up with Hikma MENA FZE, marking the introduction of its new epilepsy medicat...

South Korea's SK Biopharmaceuticals has received approval in Canada to sell its new epilepsy drug Cenobamate under the product name Xcopri. Having e...

SINGAPORE—Chinese police have detained a South Korean soccer player on allegations of bribery, the latest in a spate of enforcement actions af...

Terraform Labs co-founder Do Kwon, the mastermind behind the Terra-Luna cryptocurrency collapse, has had most of his assets in South Korea frozen, a...

South Korea’s SK Biopharmaceuticals said on Wednesday that the Israeli Ministry of Health has approved the company's new drug application (NDA...

South Korea’s SK Biopharmaceuticals on Tuesday said two of its self-developed wearable devices won the main prize in the health care category ...

On Wednesday, SK Biopharmaceuticals Co. announced that its US subsidiary, SK Life Sciences Inc., held a "National Sales Meeting" in San Diego. The p...

SK Group's new drug development subsidiary SK Biopharmaceuticals Co. will begin clinical trials for a wearable device that can detect and predict ep...

South Korean SK Biopharmaceuticals Co. said on Friday that its treatment of epilepsy "Cenobamate" has been approved for sale in France.The company l...

South Korean SK Biopharmaceuticals' epilepsy treatment Cenobamate has seen rapid growth on the US market.The company on Thursday said the medic...

South Korea’s SK Biopharmaceuticals Co. has signed a deal to license out its technology for Cenobamate, an antiepileptic drug, to Brazil&rsquo...

South Korea's SK Biopharmaceuticals Co. has dipped its toes into the rapidly growing digital healthcare market by investing in Cala Health, a US-bas...

South Korean SK Biopharmaceuticals Co. launched its epilepsy treatment Cenobamate in the UK, rapidly expanding the company’s presence in Europ...

South Korea’s SK Biopharmaceuticals Co. said on Friday it aspires to become one of the world’s top 10 healthcare companies by 2030 with ...